October 9, 2024 08:03 AM EDT

Clearside shares jump as reformulated TKI drug passes mid-stage test in wet AMD

Ayisha Sharma

News Reporter

Clearside Biomedical reported positive results from a Phase 2b trial of its tyrosine kinase inhibitor in patients with wet age-related macular degeneration, bolstering its prospects …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Clearside shares jump as reformulated TKI drug passes mid-stage test in wet AMD

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

David Baker, Demis Hassabis and John Jumper win chemistry Nobel for computational protein prediction and design

Purespring nabs $105M to take gene therapy into the clinic as IgAN field matures

AI biotech insitro partners with Lilly on metabolic disease drugs

Kevin Tang's Concentra swoops in on another struggling biotech, offering to buy Kezar

Basecamp raises $60M to travel the globe and fill AI data gaps, signs deal with David Liu

Nobel Prize winner Demis Hassabis talks about his vision for Isomorphic and AI’s future in biotech

Clear­side shares jump as re­for­mu­lat­ed TKI drug pass­es mid-stage test in wet AMD

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Clearside shares jump as reformulated TKI drug passes mid-stage test in wet AMD